This study is testing a radiation-free technique called contrast-enhanced ultrasound to evaluate kidney scarring, which is often caused by vesico-ureteral reflux (VUR). This technique uses a contrast agent called Lumason (Sulfur Hexafluoride Lipid Type A Microspheres) injected into a vein to help doctors see kidney structures more clearly. The goal is to see if this method can replace DMSA scans, which involve radiation exposure. You might be able to join if you are between 6 months and 35 years old, have VUR, and are scheduled for a DMSA scan at Boston Children's Hospital. The study will be considered successful if the contrast-enhanced ultrasound results compare well to DMSA scans. The current status of this study is unclear.

Study design

This is an interventional study planning to enroll 70 participants. It is not specified if it is randomized or blinded.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint will be measured at 3 months after the final participant completes participation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.